CA088-1005
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 111 patients (estimated)
- Sponsors
- Juno Therapeutics, a Bristol-Myers Squibb Company
- Tags
- CAR T Cell, Cereblon E3 Ligase Modulators (CELMoDs), CD3, GPRC5D
- Trial Type
- Treatment
- Last Update
- 3 weeks ago
- SparkCures ID
- 1795
- NCT Identifier
- NCT06121843
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.